Search Results for: Prohost Portfolio

Prohost Letter #459 ~ NAFLD & NASH

Prohost Letter #459 ~ NAFLD & NASH NAFLD is Non-Alcoholic Fatty Liver Disease, and NASH is Non-Alcoholic Steatohepatitis. We will start with NAFLD.   NAFLD The Non-Alcoholic Fatty Liver Disease is caused by excessive fat building up inside the liver cells. It is obvious that what is called Non-Alcoholic fatty liver disease is not caused by alcohol. The liver disease caused by Alcohol is called …

Prohost Letter #458 ~ Obesity

Prohost Letter #458 ~ Obesity Finally, obesity is being recognized as a severe sickness. Indeed, obesity is several devastating diseases, which  include  cardiovascular diseases, high blood pressure, Type 2 diabetes, cancers, sleep apnea, breathing problems, and more.  Many studies demonstrated that effective treatments for the disease will treat all these sicknesses.  The good news is that we already have effective treatments. Part of the effective …

Discovering The Root Causes of Diseases

Prohost Letter #457 Discovering The Root Causes of Diseases   Biotech firms with solid scientific fundamentals are racing towards unveiling the root-causes of various diseases that have yet to be completely unveiled. Knowing the root causes of diseases enabled some of the clinical-stage firms and the revenues-generating firms to bring into the clinic novel advanced treatments. Improving the treatments of severe untreatable diseases depends on …

Treatments for Untreatable Diseases

Prohost Letter #456 Treatments for Untreatable Diseases The revolution in biotechnology is not meant to offer just improvements on approved and marketed drugs. We are witnessing novel investigational products demonstrating safety, efficacy, statistically significant and clinically meaningful results in treating diseases that used to be considered untreatable. They include life-threatening, devastating and fast killers’ diseases. Important To Know   Biotech firms with solid fundamentals are …
Prohost Letter #455

Prohost Letter #455

Prohost Letter #455 Introduction Our Prohost Letter disappeared for six months. Several reasons dictated our decision to temporarily halt its publication. The major reason was the devastating visit of COVID-19. COVID -19 paralyzed many countries. It devastated the world’s economy, caused catastrophic inflation and the stock market’s relentless volatility. The worst of these damages was its killing of over one million people in the United …

Shorting Biotech Firms with Solid Fundamentals

Prohost Comprehensive Letter #451 Shorting Biotech Firms with Solid Fundamentals Unfair shorting of promising stocks seems to have become the norm during the harsh circumstances that not only the United States but several other countries have been living under for more than two years. The bad circumstances in the United States seem to be motivating unfair short-sellers to take advantage of bad news and cause …

Bear Market. Bad Market. Unpredictable Market.

Prohost Comprehensive Letter #450 BEAR MARKET. BAD MARKET. UNPREDICTABLE MARKET. Stock market investors usually learn from responsible sources about the status of the factors influencing the country’s economy. This is not what’s going on today. Investors have been unaware of the facts and factors that influence the economy, which includes the soaring inflation, crude oil and gas prices, the true future of COVID-19, the Russian …

Positive News for Two Undervalued Firms in the Prohost Portfolio

Exelixis CABOMETYX Approval Exelixis (EXEL) partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), which is refractory or not eligible to radioactive iodine (RAI . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

News From Vertex and Cassava: Two Prohost Portfolio Selected Biotech Firms 

Vertex Pharmaceuticals Statistically Significant Results From Vertex VX-548 for Acute Pain Vertex Pharmaceuticals (VRTX) announced positive results from two Phase 2 proof-of-concept (POC) studies that investigated treatment with the selective NaV1.8 inhibitor VX-548 for acute pain following abdominoplasty surgery or bunionectomy surgery. Treatment with an initial dose of 100 mg followed by 50 mg . . . This content is for paid subscribers. Please click here …

Comprehensive Prohost Letter #449 – Reality

Comprehensive Prohost Letter Issues Reality The Best of words in informative texts are the smallest in number and the most truthful in contents. That’s what Prohost believes, especially in the presence of the cruel circumstances our entire planet is currently living. Last Friday, the three indexes of the stock market had their best performances since the 4th quarter of 2020. Why? We don’t know, but …

These Dangerous World Circumstances and the Prohost Portfolio

The circumstances that we find the world in today are abnormal. They are extremely intense and dangerous. We are living  an unprecedented, unexpected and inexplicable  war in Europe, which nobody seems to know how it would end up.  When it comes to the  Market, the degree of chaos, mysteries and destruction have far exceeded our ability to fairly evaluate our selected  biotech picked firms. We …

Comprehensive Prohost Letter #448

Comprehensive Prohost Letter Issues Coronavirus Variant Omicron A lot has happened since the coronavirus variant Omicron was discovered in South Africa. After having been responsible for a severe plummeting of the stock market, Omicron boosted the market after being described by many scientists as fast spreading with different yet milder symptoms when compared to those caused by SARS-CoV-1, SARS-CoV-2 (the virus that causes COVID-19) and …

Comprehensive Prohost Letter Issues

The Comprehensive Prohost Letter Issues The Comprehensive Prohost Letter Issues will constitute a chain of 7 issues. Today’s issue will include the following: Pinpointing and selecting the biotech firms that demonstrate readiness to treat untreatable, devastating diseases. Presenting an important antibody cocktail for the treatment of COVID-19. Stating our position regarding the Alzheimer’s disease firm Cassava Sciences. Pinpointing Prohost’s . . . This content is …

A Reevaluation of Prohost Biotech’s Picked Firms

Prohost Letter #446 A Reevaluation of Prohost Biotech’s Picked Firms We have already pinpointed some of the devastating and life-threatening diseases that have yet to find treatment. Prohost’s plans are about discovering small &/or large biotech or biopharma firms that demonstrate scientific capability for treating or curing these diseases. Most of the firms that we picked for investment in yesteryears had solid scientific and managerial …

Important News and Results from Two Companies in the Prohost Portfolio

Important News and Results from Akero Therapeutics Akero Therapeutics (AKRO) announced that full results of the main portion of its Phase 2a BALANCED trial in biopsy-confirmed NASH patients with F1-F3 fibrosis have been published in Nature Medicine. The study shows investigational NASH Drug Efruxifermin (EFX) reduced liver fat to normal levels and reversed fibrosis after 16 weeks . . . This content is for paid subscribers. …

Intellia Therapeutics and Regeneron Pharmaceuticals: Yes, it is a Miracle!

Prohost Portfolio PLUS #6 Yes, it is a Miracle! Intellia Therapeutics and Regeneron Pharmaceuticals This miracle news from Intellia Therapeutics and Regeneron Pharmaceuticals came Saturday, a day when the Market is taking rest from the usual yo-yoing of good/bad reasons and no reasons. This miracle of great news emanated from Intellia Therapeutics. The first-ever clinical data from a trial that supports safety and efficacy of in vivo CRISPR …

Vir Biotechnology

Prohost Portfolio PLUS #5 Vir Biotechnology Vir Biotechnology (VIR) combines cutting-edge technologies with immunologic insights to prevent and treat serious infectious diseases. Proof of concept and feasibility has been offered as demonstrated in early and mid-trial results; the firm, together with GlaxoSmithKline, have applied for the approval . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Celldex Therapeutics See Also: More of Your Questions Answered

Prohost Portfolio PLUS #4 Celldex Therapeutics Celldex Therapeutics (CLDX) stock is gaining momentum. On April 12, 2021 Celldex announced its presentation of promising data from its growing bispecific platform at the American Association of Cancer Research (AACR) Annual Meeting 2021 held between April 10th – 15th. The Company described the discovery . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

CureVac N.V.

Prohost Portfolio PLUS #3 CureVac N.V. We were looking forward to learning more important details about the German firm, CureVac N.V. (CVAC), when the company announced business updates and financial results for its fourth quarter and full-year 2020. The reason for our interest was the fact that the U.S. was looking to take over this firm two years ago to no avail. A more important …

Re-Working Some Evaluated Biotechnology Firms

Prohost Portfolio PLUS #2 Re-Working Some Evaluated Biotechnology Firms Exelixis: 2020 and 2021 Wondering why Exelixis’ (EXEL) stock has looked paralyzed for more than two years? To know better about Exelixis the entrepreneur and Exelixis the creative scientific institution, we decided to go to the recorded Exelixis history, financial results and scientific . . . This content is for paid subscribers. Please click here to subscribe …

Your Questions, Our Answers

Prohost Portfolio PLUS (formerly The Week in Review) Your Questions, Our Answers In the upcoming issues of Prohost Portfolio PLUS, as with all our Tables, we will include observations and target changes as well as any current news we feel is important enough to be reviewed and/or discussed. We hope you will visit us weekly for updates. Included in this Issue are the Following: Anixa …

A Flashback and Future Projections

Prohost Letter #445 A Flashback and Future Projections 1. A Follow-Up on Recently Posted News from ProhostBiotech 2. Answering Questions 3. Development-Stage Firms to Outperform 4. Oversold Revenue-Generating Firms 5. Tables with FAIR 2021 Targets for the Prohost Selected Firms In This Issue We Discuss the Following Firms: Anixa Biosciences (

Prohost Letter #444

Prohost Letter #444 The End of the Year Issue was delayed because our 2020 Prohost Portfolio stocks’ targets for the year failed to materialize; nobody not even the authorities were capable of predicting the pandemic, which continues to plague the world. As 2021 approached, we were unable to the End of the Year issue on time as we lacked the information required for the fair …

Are We Saying Goodbye to Common Sense?

Prohost Letter #441 Biotechnology Companies’ Evaluations Are We Saying Goodbye to Common Sense? The SARS-CoV-2 Vaccines It is said that the difference between the SARS-CoV-2 coronavirus (COVID-19), which is causing the pandemic around the world we are currently suffering from, and other coronaviruses like SARS and/or MERS is that SARS-CoV-2 ability to replicate in the human bodies' respiratory system’s upper airways more than the others. …

Novel Coronavirus: The Therapeutics

Prohost Letter #440 Coronavirus The Therapeutics Gilead’s Remdesivir Treating COVID-19 patients requires therapeutic products that can deal with moderate and severe persistent symptoms that are unwilling to ease or completely disappear after weeks of isolation, when following the distancing and wearing masks. The first product proven effective and safe to be granted FDA Emergency Use Approval (EUA) happens to be remdesivir from Gilead Sciences (
The World Focus is on COVID-19 Treatments and Vaccines

The World Focus is on COVID-19 Treatments and Vaccines

The Week in Review #50 The World FOCUS is COVID-19 The world FOCUS right now is on life-saving accomplishments for COVID-19. In addition to safety measures that are being adopted by most citizens the following realizations that accomplishments might lead to a clear victory over the life-threatening novel coronavirus. They are: Successful Treatments that will alleviate the severity of symptoms from COVID-19 that is causing …
Prohost Letter #439

Prohost Letter #439

Prohost Letter #439 The Coronavirus Outbreak - COVID-19 The news announced that the coronavirus (now known as COVID-19) outbreak would affect not only people’s health and survival but the world’s economy, Wall Street’s performance, and especially the international giant industrial firms that are committed to China. British AstraZeneca (AZN
Prohost Letter #438 ~ The End of the Year Issue 2019

Prohost Letter #438 ~ The End of the Year Issue 2019

Prohost Letter #438 End of the Year Issue  2019 Happy New Year 2020 The NASDAQ reached 9000 for the first time in the market history on December 30, 2019. However, on the last trading day of 2019, the Nasdaq Composite Index closed at 8,945.99 after giving back 60.62 points or 0.7%. During the departed year, however, the stock exchange was boosted by the outperformance of …
The Week in Review #48 ~ Holiday Edition

The Week in Review #48 ~ Holiday Edition

The Week in Review #48 Holiday Edition ******************** Merry Christmas and Happy Hanukkah! We Wish You a Happy New Year Filled with Excellent Health, Peace of Mind, Prosperity and Happiness What a Year for Biotechnology What happened in the biotech sector toward the end of 2019 is briefed in this Review as we focus on the performance of our picked firms’ stocks’ prices. We will …
More fom the Prohost Portfolio

More fom the Prohost Portfolio

More from the Prohost Portfolio with Our Observations Gilead (GILD) has cash and new products reaching the market, and its agreement with Galapagos will soon bring another drug approval. We will tackle Gilead’s news and all the firms in the Prohost Portfolio with more details in the upcoming Year in . . . This content is for paid subscribers. Please click here to subscribe or here to …
An All Time High Market

An All Time High Market

Prohost Letter #437 An All Time High Market More Prohost Picks Have Reached the 2019 Targets The stock market performance has reached an all-time high with more of our picks reaching or nearing the Prohost 2019 price targets. There are stories to tell about some devastated stocks which many believed were dead and buried but were surprisingly resurrected, and their stocks are going up. Another …
What A Week For Biotechnology

What A Week For Biotechnology

The Week in Review #47 What A Week For Biotechnology Synopsis In this “Week in Review” there is no complicated scientific and clinical information, leaving the details to the articles that we usually post on the Prohost website. Most of the Prohost picked firms’ Q3 financial results have beaten expectations. Three firms have reached the Prohost 2019 targets, and more firms have outperformed, with some …
Karyopharm Therapeutics: Is a Star Born?

Karyopharm Therapeutics: Is a Star Born?

Karyopharm Therapeutics Third Quarter Financial Results Generated Revenues For the first time since its establishment Karyopharm Therapeutics (KPTI) financial results report revenues from a strong launch of its first approved product. Indeed, the firm’s third-quarter 2019 financial results are the first quarter in which Karyopharm generated revenues. In early July the U.S. FDA granted the company’s product Xpovio® (selinexor . . . This content is for …
The Quarterly Financial Results

The Quarterly Financial Results

The Week in Review #46 The Quarterly Financial Results The quarterly financial results that analysts and investors relied on for years to evaluate biotech firms, including development stage firms, seem to change. Investors have finally realized that development-stage firms have no marketed drugs and no revenues, hence, no incomes and should be evaluated based on the clinical trial results of their pipeline products. They saw …
What Was Seen and What Was Ignored

What Was Seen and What Was Ignored

The Week in Review #44 Quarterly Financial Results What Was Seen and What Was Ignored History and self-experiences enabled investors to expect and swallow biased reactions following the announcements of the biotech sector’s firms’ quarterly results. Investors have long been expecting negative reactions towards small development-stage biotech firms following the announcement of their quarterly financial results. What they did not expect is for the same …
This Past Week

This Past Week

The Week in Review #43 This Past Week After hearing hints about the trade war between China and the United States being avoided the market reversed course from faltering to flying at the speed of light. This trade war replaced all important factors that would usually affect the market performances. Unemployment is the lowest since 1969 and is expected to cause a bullish market, but …
During the Departed Week

During the Departed Week

The Week in Review #42 During the Departed Week The week started with the market losing over 1000 points and ended recuperating a large extent of the losses. Desperate during the market’s plummeting, some investors were happy for the rebound and some were confused and skeptical about what the unpredictable market might bring next. In the latest Prohost Letter #436, the losses in prices of …
What Are We Experiencing Now?

What Are We Experiencing Now?

Prohost Letter #436 What Are We Experiencing Now? The bizarre market underperformance progressing rather than regressing and the good economy and the employment gains are the least utilized factors after being the most influential on the stock market performance. We are witnessing the most bullish analysts being confused, hesitating to give their followers a crystal clear explanation about the market’s skepticism, anger and volatility. The …
The Value of the Biotech Companies Continued

The Value of the Biotech Companies Continued

Prohost Letter #435 The Value of the Biotech Companies A Continuation of Prohost Letter #434 A Recap The biotech near and long-term values, we insist, must be based on the firms’ scientific capabilities, products’ potentials and financial results. In the past months the stocks evaluations by bloggers, and some assessors, have been tailored to mislead investors into serving the purposes of the manipulators’ weird agendas. …
About RegenxBio’s Agreement with Clearside Biomedical and More

About RegenxBio’s Agreement with Clearside Biomedical and More

Diseases of the Back of the Eye Diseases of the back of the eye, such as: age-related wet macular degeneration, diabetic retinopathy and diabetic macular edema, are currently managed with injections of anti-vascular endothelial growth factor (anti-VEGF) drugs into the gel-like substance (the vitreous humor) that fills the eye between the lens and the retina. The currently used age-related wet macular degeneration injections are: Lucentis, which belongs …
The Bizarre Market

The Bizarre Market

The Week in Review #41 We Are Still Witnessing … The bizarre market performance that started in early 2019: In the past couple of months the great enthusiasm and response of the market to the undeniably strong economic indicators and the lowest unemployment figures turned, for mysterious reasons, to a perturbed-looking volatile market beast. The biotech stocks have given back most of their deserved gains …
The Value of the Biotech Companies

The Value of the Biotech Companies

Prohost Letter #434 Special Issue The Value of the Biotech Companies With a strong economy and an unemployment rate reaching the lowest percentage in decades we are witnessing strange, if not bizarre, market performance since the beginning of 2019. From the early signs of economic strength the stock market reacted explicitly to positive, economic news. Later, the enthusiastic market turned dispirited and volatile. The biotech …
Treating Hemoglobinopathies

Treating Hemoglobinopathies

Prohost Letter #433 Treating Hemoglobinopathies The most common genetic blood disorders are the hemoglobinopathies: sickle cell disease (SCD) and beta-thalassemia. Millions of people around the world are affected by these two conditions in which genetic defects impact the hemoglobin production.We called the past week “The Hemoglobinopathies’ Week”. Important and impacting news came with promising clinical trials data from two products aimed at treating sickle cell …
The ASCO 2019 Special Edition

The ASCO 2019 Special Edition

Prohost Letter #432 The ASCO 2019 Special Edition SPRAYING FEAR The Victims Are The most disturbed victim of the instigated and irrelevant fear against investing in the stock market is the market itself. Indeed, baseless fear campaigns frighten positive investors while encouraging short-selling investors to maximize their selling which intensifies the markets volatility. We have been experiencing this phenomenon since the beginning of 2019. Market …
Genomes, Genes and Gene Therapies

Genomes, Genes and Gene Therapies

Prohost Letter #431 Genomes, Genes and Gene Therapies In this issue of the Prohost Letter we focus on genomes, genes and gene therapies. National DNA day is April 25th . On this day we commemorate: James Watson, Francis Crick, Maurice Wilkins, Rosalind Franklin and other of their collegues who published papers on the structure of DNA in 1953. It is an opportunity to celebrate the …
The Week in Review #40

The Week in Review #40

  Conquering NASH Gilead and Novo Nordisk Conquering NASH What was Gilead Sciences' (GILD) announcement at EASL? What is Gilead doing to find effective treatments for NASH? Why would Novo Nordisk's (
Prohost Letter #430

Prohost Letter #430

Prohost Letter #430 Rheumatoid Arthritis and Gilead The FINCH 1 trial: Has it reached its primary endpoints? How did the drugs respond as compared to placebo; what is the disability index, clinical remission, disease activity rate and safety results? What’s happening with Gilead’s HIV product? Read about Gilead’s collaboration with Galapagos. See how Prohost answers these questions in this issue #430 of the Prohost Letter. …
During the Departed Week

During the Departed Week

The Week in Review #39 During the Departed Week Three Prohost Portfolio Picks Hit Their 52-Week Highs The three picks referred to in the above title are, Novartis (NVS), Array (AARY) and Ionis (IONS). Previous Prohost Letters discussed Novartis and Array and continued to remind that they are Prohost favorites. The time has come to take a deeper look at Ionis; starting with the reasons …
End of the Year Decisions ~ Part 4

End of the Year Decisions ~ Part 4

Prohost Letter #429 End of the Year Decisions ~ Part 4 We picked for our portfolio what we believed are biotech firms with breakthrough technologies  and promising products. The few firms that failed us in the beginning were lacking good management or suffered from greedy management. Later, when we liked biotech companies, we picked them only when we confirmed their management’s capability and honesty... &nbsp …
Good news and setbacks during the departed week

Good news and setbacks during the departed week

The Week in Review #38 SYNOPSIS Good News and Setbacks During the Departed Week from the Prohost Portfolio FIRMS WITH GOOD NEWS SPARK THERAPEUTICS The most important happening, with the most exciting positive impact, has come this time from our picked gene therapy company, Spark Therapeutics (ONCE). It was electrifying news, which announced acquisition by Roche (RHHBY) of Spark Therapeutics; at a price of $114.50 …
The Week in Review #37

The Week in Review #37

From the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Prostate Cancer A presentation by Bayer demonstrated improvement in the treatment of non-metastatic castration-resistant prostate cancer. Separate presentations by Bristol-Myers and Janssen also demonstrated improvement in metastatic castration-resistant prostate cancer. Non-Metastatic Castration Resistant Prostate Cancer Bayer Results from pivotal Phase 3 ARAMIS trial with Bayer’s (BAYRY) and Orion Corporation’s jointly-developed product darolutamide plus …
End of the Year Decisions ~ Part 3

End of the Year Decisions ~ Part 3

Prohost Letter #428 End of the Year Decisions ~ Part 3 In Part 3 of this series we selected two firms, both were recently added to the Prohost Portfolio. The first firm, FortySeven (FTSV), focuses on an immunotherapy that differs from the breakthrough blockbuster checkpoint inhibitors on the surface of the T Cells. FortySeven’s products target checkpoint proteins on both cancer cells and macrophage cells. The latter …
Now You See It, Now You Don’t

Now You See It, Now You Don’t

Now You See it, Now You Don’t Deliberate Omissions of Real Facts Real facts might be displayed or concealed depending on the news announcers’ or bloggers’ self-interests. The following contains cases of deliberate or unintentional omission of facts that led to the decline of fundamentally sound biotech and biopharmaceutical firms in bullish market during the departed trading week . . . This content is for paid subscribers. Please …
End of the Year Decisions Part 2

End of the Year Decisions Part 2

Prohost Letter #427 End of the Year Decisions ~ Part 2 As a result of the unexpected volatility in the stock market, we carefully reassessed each and very stock we picked for the Prohost Portfolio. Consequently, we had to change many of our 2019 targets in all 7 tables which represents the whole portfolio of companies we believe are offering lucrative investment opportunities. On January 3, …
End of the Year Decisions ~ Part 1

End of the Year Decisions ~ Part 1

Prohost Letter #426 End of the Year Decisions ~ Part 1 We decided to make this Prohost Letter a guideline of our opinion regarding all the firms we picked for the Prohost Portfolio, rather than the few firms that we promised to elaborate on in the Prohost Portfolio that we posted on January 1, 2019 at the Prohost Biotech website . . . This content …
The NEW Prohost Portfolio for 2019

The NEW Prohost Portfolio for 2019

The NEW Prohost Portfolio Small Important Changes We are making some very small but important changes in our portfolio. Each table represents a sector among the various technological divisions that create more effective products currently being used, or intended to be used, in the management of various illnesses...
AstraZeneca: Excellent collaborations. Moderna Therapeutics: Turning public. Will Prohost add it to its Portfolio as promised?

AstraZeneca: Excellent collaborations. Moderna Therapeutics: Turning public. Will Prohost add it to its Portfolio as promised?

In the NEWS AstraZeneca (AZN) announced a collaboration with Cancer Research UK to launch a center of excellence in genetic screening, cancer modelling and big data processing aimed at accelerating the discovery of new cancer medicines. During the announcement of the news, Mene Pangalos, the firm’s Executive Vice President, Innovative Medicines & Early Development, said, the best science doesn’t happen in isolation, which is why AstraZeneca …
Politics and the Market

Politics and the Market

The Week in Review #35 Politics and the Market The market tumbled today as Theresa May, the Prime Minister of England, delayed the Brexit vote!  The question becomes, what will be put forth next as a legitimate reason for bringing the market down and eroding investors’ gains? The weather? A war among gangs in a fourth-world country? Maybe the resignation of the chairman of a …
When common sense fails to explain market performance

When common sense fails to explain market performance

Prohost Letter #425 When Common Sense Fails to Explain the Market Performance It is not unusual for the stock market to be in a selloff mood for a few days. However, in the last couple of months, the market unexpectedly plunged deep into the ocean of the unknown. The exaggerated volatility was nerve-wracking for professional analysts. This is especially true for candid analysts who base …
Improving on immunotherapy and preventing one of its serious side effects

Improving on immunotherapy and preventing one of its serious side effects

The Week in Review #34 Improving on Immunotherapy and preventing one of its serious side effects. Removal of glutamine leads to a substantial reduction in cell growth or induces cell death in certain types of cancer cells, indicating that these cells are dependent on, or "addiected" to, glutamine. Normal cells do not depend much on glutamine . . . This content is for paid subscribers. …
We call it the bad market

We call it the bad market

The Week in Review #33 WE CALL IT THE BAD MARKET The Federal Reserve’s raising of the interest rate does not and should not mean a demise of the companies trading on the NASDAQ and other stock exchanges. The biotech group of firms with strong scientific fundamentals will not stop innovating and bringing breakthroughs to millions of people who are desperate for them if an …
Positive News

Positive News

The Week in Review #32 POSITIVE NEWS PROTEOSTASIS THERAPEUTICS Cystic Fibrosis Two days ago, a clinical-­stage small firm called Proteostasis Therapeutics (PTI) announced positive preliminary results from ongoing Phase 1 cystic fibrosis studies. The trial involved the firm’s proprietary combination therapy doublet, PTI-­808 + PTI-­801...
Following the Stars. Less Science and More Logic

Following the Stars. Less Science and More Logic

Prohost Letter #424 Following the Stars Less Science and More Logic We reiterate that while a human star is born every once in a while on Earth, several stars born daily in research labs may be designated every other day by the FDA and other health regulatory agencies around the world. These agencies call these potential stars’ breakthrough drugs, but not all the molecules designated …
Outperformance, Underperformance and Volatility

Outperformance, Underperformance and Volatility

The Week in Review #31 IN THE DEPARTED WEEK NOVEL MIGRAINE DRUGS ARE APPROVED ELI LILLY AFTER AMGEN AND TEVA In less than five months, the FDA approved three products belonging to four drug developers – all targeting calcitonin gene-related peptide (CGRP) for the prevention of migraine headache. The latest for Eli Lilly (LLY) last week . . . This content is for paid subscribers. …
Three important news

Three important news

The Week in Review #30 FROM THE DEPARTED WEEK In the past week, we came across a lot of news announcing research, clinical trial results, collaborations, product approvals and acquisitions. Much of the departed week’s news though, does not represent complete stories, especially the ones related to research. They represented early works in progress offering no concrete results that we can evaluate. Important news for …
What is looking good in the aggressive portfolio

What is looking good in the aggressive portfolio

The Week in Review #29 PROHOST AGGRESSIVE PORTFOLIO  - The aggressive portfolio hosts biotech firms with solid scientific fundamentals and prominent scientists whose stocks have plummeted following some setbacks. A setback could be a failure of an investigational product to meet the endpoints of its clinical trial or that the small biotech firm has taken long to achieve its goals . . . This content …
Outperforming, favorite, and undervalued biotech firms

Outperforming, favorite, and undervalued biotech firms

The Week in Review #28 The approval of revolutionary products created by biotech firms with solid scientific fundamentals, superior scientists and advanced technologies is what motivates us to pick for investment biotech and biopharmaceutical firms. So, let’s see what has been approved in the parting week  from firms that we picked for investment.       IMPORTANT APPROVALS       Prohost Picked Firm     …
Bombarding future treatment approaches

Bombarding future treatment approaches

The Week in Review #27 PRIORITY TOPICS: CRISPR GENE EDITING, GENETIC ENGINEERING & ANTISENSE TECHNOLOGY The choice of these topics was dictated by investors who follow the sell side preaching. These negative investors decided to cause a selloff in all kinds of therapeutics that act at the root cause of diseases, i.e., the malfunctioning genes. These therapeutics are what we call the future treatments and cures. Indeed, during …
Victims of fear and misunderstanding

Victims of fear and misunderstanding

ProhostLetter #423 TOMORROW’S THERAPEUTICS TODAY For a more or less fair evaluation of biotechnology and pharmaceutical firms, analysts currently rely for their assessment on criteria that include quarterly financial results, products’ sales revenues, and year over year growth of each and every marketed therapeutic. When it comes to clinical-stage firms, the logic implies that these criteria cannot be relied on for evaluation, as most of …
Stories about research, clinical trials results and an FDA ruling

Stories about research, clinical trials results and an FDA ruling

The Week in Review #26 IN THE BIOTECH WORLD - RESEARCH - IMPROVING CRISPR GENE EDITING The problem cited with gene editing is that the editing may stay switched on after it succeeded in reaching its goals. To prevent further unwarranted mutations, scientists from the Bath and Cardiff University have invented a switch that aims at controlling protein expression in cultured cells and mouse embryos with the …
Finding reasons for underperforming stocks

Finding reasons for underperforming stocks

The Week in Review #25 When Stocks Plummet for No Relevant Reasons Sometimes investors need to know why some of their stocks plummet when no bad news is broadcast anywhere and when firms announce terrific news promising progressive growth. Yesterday was one of those days where reasons for stocks’ deviant, and probably unwarranted, negative performances must be identified. Let’s have a look at what happened during …
Our outperforming firms and more

Our outperforming firms and more

The Week in Review #24 Biotech Stocks’ Performances, Products on the Move and Biotech Research Biotechnology stocks’ performance should be based on the firm’s intrinsic news that announces the power of their technologies and the successes or failures of their lead products and, to a lesser extent of their early-phase trials’ products. To be taken in consideration too are their financial statuses, especially of firms …
Good News, Bad News & Comebacks. See Also: ASCO Results

Good News, Bad News & Comebacks. See Also: ASCO Results

The Week in Review #23  ASCO  2018 - Small  publicly-­traded  oncology  biotech  firms,  large  oncology  biotech  firms,  and  giant  biopharmaceutical  firms,  in  addition  to  some  private  biotech  companies,  all  presented  results  and  observations  about  their  cancer  drugs  at  the  2018  American  Society  of  Clinical  Oncology  (ASCO)   meeting.  Most  presentations  were  useful,...
New stock selection and re-evaluation

New stock selection and re-evaluation

Prohost Letter #422 SUMMARY OF THE PAST ISSUE ARTICLE - REVISITING PROMISING FIRMS (PART1) - The firms we tackled in the past issue comprised: 1. Firms we liked and added to our portfolio. 2. Firms we posted their good news, but did not select... 
Revisiting Biotech Companies We Highlighted

Revisiting Biotech Companies We Highlighted

Prohost Letter #421 PRIVATE  LESSONS - Stock prices of publicly-­traded biotech companies oscillate for the same reasons other industries’ stock prices swing all day long. The fluctuations are the outcome of investors’ and daily traders’ unrelenting buying and selling . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
AveXis Drug’s Data for Spinal Muscular Atrophy Highlights Gene Therapy

AveXis Drug’s Data for Spinal Muscular Atrophy Highlights Gene Therapy

The Week in Review #21 Part 2 THE  MARKET (2) - Our remarks in the past Week in Review included our confidence that the attempts by negative investors to drive the market crazy will not deprive the market from its innate capability to sense and react to the authentic factors it usually reacts to . . . This content is for paid subscribers. Please click here to …
The Biotech Revolution is Alive and Speeding

The Biotech Revolution is Alive and Speeding

The Week in Review #21 Part 1 THE MARKET - Like symphonic orchestras that bring to the listeners’ ears, minds and souls melodies composed by legendary authors, the stock market reflects what’s going on in the world, which would positively or negatively impact the lives and well being of the earth’s residents . . . This content is for paid subscribers. Please click here to subscribe or here to …
Real Breakthroughs

Real Breakthroughs

Prohost Letter #420 REAL BREAKTHROUGHS - One Has Already Been Used and the Other Has Extraordinary Promises In  the  NEWS - THE POWER OF CHECKPOINT INHIBITOR IMMUNOTHERAPY WOW It is about the checkpoint inhibitors immunotherapy, which is bringing to the world of cancer a stunning revelation of a combination treatment offering an almost cure for a lung cancer...
Bull or Bear

Bull or Bear

The Week in Review #20 THE MARKET - My friend asked: “Are  you  scared?” “Of  what?” I asked “The  market?” The  market? No,” I  said.  We are afraid of those who are rendering the market nervous and  temporarily confused, as we observed while monitoring its volatility.  The market has never been chronically confused . . . This content is for paid subscribers. Please click here to …
The Prohost Portfolio: Updating the Stock Targets

The Prohost Portfolio: Updating the Stock Targets

Prohost Letter #419 RE-­EVALUATION ONLY - The Prohost Portfolio comprises biotechnology and biopharmaceutical companies, that we believe have solid scientific fundamentals and dedicated managements. All the firms in the portfolio, except a few, have proprietary technologies, which enable the firms’ scientists to design in house safer and more effective new molecular entity therapeutic molecules . . . This content is for paid subscribers. Please click here …
Highlighting Gene Editing Firms

Highlighting Gene Editing Firms

The Week in Review #19 Targeting the Root-­Cause of Diseases - Investing in the Future is Currently the Best Way - Stopping aberrant genes from causing diseases has taken time to move from wishful thinking to reality. Through trial and error, various different approaches have been tested over the years, including attempts at genetic engineering... &nbsp . . . This content is for paid subscribers. …
Observing Queer Stories

Observing Queer Stories

Prohost Letter #418 Observing Queer Stories  PORTOLA - Portola (PTLA) has been granted approval of an important factor Xa inhibitor Bevyxxa (betrixa-­ban for extended prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for a life-­threatening VTE . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
In the Limelight

In the Limelight

The Week in Review #18 The Market - The stock market recuperated most of its losses while analysts preferred to abstain from forecasting and remain bystanders during the market volatility.  Although the causes of volatility have yet to be delineated, some philosophers in the field dared to attribute it as a market’s own mind’s judgment . . . This content is for paid subscribers. Please …
A Wild Wild Week

A Wild Wild Week

The Week in Review #17 A Wild Wild Week - The stock market looked as if it rejected all analysts’ opinions about the stocks they believed were “undervalued” and adopted only their opinion on what they believed are overvalued. As a result, the market decided to dive,... &nbsp . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Private Lessons and More

Private Lessons and More

Prohost Letter #417 Private Lessons - These lessons are overdue and we had to do this homework before we go into further evaluations of our picks and introduction of new companies as we promised in the past issue. We believe that the Prohost readers, the fans and the critics should know how and why we pick our biotech stocks . . . This content is …
Another Week of Outperformance

Another Week of Outperformance

The Week in Review #16 More Exciting Rallies in Prohost Picks - The past week and for several week fascinating outperformances have been seen for many of the Prohost Portfolio stocks. We continue to articulate that the good news is not only in the stocks’ rallies, but also in the outstanding stories behind them . . . This content is for paid subscribers. Please click here …
The Year in Review Part 2

The Year in Review Part 2

Prohost Letter #416 Part 2 2017 - A YEAR OF BREAKTHROUGH TECHNOLOGIES, BREAKTHROUGH PRODUCTS, IMPROVEMENTS ON PROMISING BREAKTHROUGH TREATMENTS, DECIPHERING IMPORTANT LIFE SCIENCE MYSTERIES, PINPOINTING BIOLOGICAL PATHWAYS FOR TREATMENT RESISTANCE, MIRACLE CURES, AND… A LOT OF DISTORTED NEGATIVE INTERPRETATIONS - Prioritizing our choices of breakthroughs has been a dilemma . . . This content is for paid subscribers. Please click here to subscribe or here to log …
The Year in Review Part 1

The Year in Review Part 1

Prohost Letter #416 Part 1 The Year In Review - 2017 Unheard of Programs - AN AWESOME YEAR for the biotech sector regarding its accomplishments. Many of the accomplished programs were unheard of regarding the degree of their positive impact on medical practice. Unfortunately, many of these accomplishments, which included the making of new discoveries, the creation of novel advanced technologies and the design of …
Last Week’s Promising News

Last Week’s Promising News

The Week in Review #13 From the Prohost Portfolio - 1. Betting on the technology - HALOZYME - As expected, the pulse of fat agreements with HALO is accelerating . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Prohost Letter #415

Prohost Letter #415

Prohost Letter #415 New Promising Technologies PROTAC - A Technology That Offers a Superior Class of Drugs PROTAC is an approach that created a new class of drugs described as superior and far less toxic than targeted drugs known to block disease-­causing proteins. The technology belongs to a private Company called Arvinas . . . This content is for paid subscribers. Please click here to subscribe …
Answering Your Questions

Answering Your Questions

The Week in Review #12 Answering You - Many questions still need answers in the biotech’s fast moving universe and we are doing our best to answer them.  We found out that we should start answering questions even though we are in a middle of a reasonably short vacation that we dared to take after over 5 years of constant working . . . This …
The Week in Review #11

The Week in Review #11

The Week in Review #11 A New Era - Faster than the speed of light, the management of diseases is shifting from fast improvement to a total gigantic unprecedented change. Some of the conquering approaches towards providing long-­lasting cures look as if the outcome of magic rather than mere science . . . This content is for paid subscribers. Please click here to subscribe or here to log …
The Week in Review #10

The Week in Review #10

The Week in Review #10 NO CONSPIRACY THEORIES - But this is what’s happening - In the past issue of The Week in Review, we wrote about the irrational pattern of selling the biotech stocks during the announcement of the quarterly results and how some investors are taking advantage of this pattern to sell their stocks before the quarterly results . . . This content …
The Week in Review #9

The Week in Review #9

The Week in Review #9 KNOCKING DOWN THE BIOTECH STOCKS - Knocking down the biotech companies’ stocks during the announcement of the quarterly reports is no news. Most investors in the stock market, especially those who invest in the biotech sector have become familiar with this pattern . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Prohost Letter #414

Prohost Letter #414

Prohost Letter #414 GIANTS & DWARFS - We believe it’s a useful idea bringing The Week in Review into the Prohost Letter this time. We thought it would be easier for the readers to get last week’s updates and comments together with the Letter’s subjects and its Prohost Portfolio’s observations. In the Week that said au revoir, things happened that are worth citing. New development-stage …
Tracing Large Pharmaceutical Companies’ Choices

Tracing Large Pharmaceutical Companies’ Choices

The Week in Review #8 Potential biotech winners inspired through COLLABORATION - When successful top-­tier drug developing firms such as Amgen (AMGN) or Merck (MRK) sign strategic collaborating agreements with small development-­stage biotech firms,...   &nbsp . . . This content is for paid subscribers. Please click here to subscribe or here to log in.